Jefferies lifts Quest Diagnostics stock target to $190, keeps Buy rating

The report concluded with a positive outlook on Quest Diagnostics (NYSE:DGX)’ future, noting its improving growth trajectory and the protective buffer it has against challenges in the healthcare industry. Jefferies maintained their Buy rating and raised their price target to $190, signaling confidence in the company’s stock performance going forward. With a P/E ratio of 21.78 and a steady dividend yield of 1.93%, the stock has shown remarkable stability, delivering a 23.2% total return over the past year. For deeper insights into Quest Diagnostics’ valuation and growth prospects, investors can access the detailed Pro Research Report available on InvestingPro, which provides comprehensive analysis of this healthcare sector leader. With a P/E ratio of 21.78 and a steady dividend yield of 1.93%, the stock has shown remarkable stability, delivering a 23.2% total return over the past year. For deeper insights into Quest Diagnostics’ valuation and growth prospects, investors can access the detailed Pro Research Report available on InvestingPro, which provides comprehensive analysis of this healthcare sector leader.

The report concluded with a positive outlook on Quest Diagnostics’ future, noting its improving growth trajectory and the protective buffer it has against challenges in the healthcare industry. Jefferies maintained their Buy rating and raised their price target to $190, signaling confidence in the company’s stock performance going forward. With a P/E ratio of 21.78 and a steady dividend yield of 1.93%, the stock has shown remarkable stability, delivering a 23.2% total return over the past year. For deeper insights into Quest Diagnostics’ valuation and growth prospects, investors can access the detailed Pro Research Report available on InvestingPro, which provides comprehensive analysis of this healthcare sector leader.

Jefferies highlighted the company’s expectations for a slower pace of mergers and acquisitions following the integration of deals completed in 2024. Despite this anticipated deceleration, the firm expressed continued confidence in Quest Diagnostics’ growth prospects. The analysts underscored the company’s resilience against broader healthcare sector threats and found its valuation appealing.

The report concluded with a positive outlook on Quest Diagnostics’ future, noting its improving growth trajectory and the protective buffer it has against challenges in the healthcare industry. Jefferies maintained their Buy rating and raised their price target to $190, signaling confidence in the company’s stock performance going forward.

In other recent news, Quest Diagnostics reported a successful Q4, with earnings and revenue surpassing analyst expectations. The company posted an adjusted earnings per share of $2.23, beating the consensus estimate of $2.19, and revenue of $2.62 billion, exceeding expectations of $2.58 billion. This represents a notable 14.5% increase year-over-year.

Additionally, Quest Diagnostics completed eight acquisitions in 2024, including LifeLabs in Canada, contributing to the robust Q4 results. The company’s Chairman, CEO, and President, Jim Davis, expressed confidence in the business’s core strength, continuing robust utilization, and momentum from the recent acquisitions.

Looking forward, for the full year 2025, Quest Diagnostics expects an 8.4% to 9.9% growth in revenue, forecasting between $10.70 billion and $10.85 billion. Adjusted earnings per share are projected to range from $9.55 to $9.80.

The company also raised its quarterly dividend by 6.7%, increasing it to $0.80 per share, marking these as the recent developments in the company’s financial landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.